ClinicalTrialsFinder
RecruitingNot ApplicableNCT06109870

Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening

Sponsor

M.D. Anderson Cancer Center

Enrollment

920 participants

Start Date

Oct 30, 2023

Study Type

INTERVENTIONAL

Conditions

HPV

Summary

Cervical cancer is a disease that is preventable through vaccination against the virus that causes it, human papillomavirus (HPV), and through screening and treatment of cervical disease before it becomes cancet.

Eligibility

Min Age: 18 Years

Inclusion Criteria8

  • To be eligible to participate in this study, an individual must meet all of the following criteria:
  • Provision of signed and dated informed consent form
  • Currently resident in RGV or other low-resource community in Texas
  • Stated willingness to comply with all study procedures
  • Females; Age ≥25 years
  • Have no history of hysterectomy with removal of the cervix
  • Have no history of cervical cancer or high-grade dysplasia
  • Have not had a Pap test in the past 3.5 years or Pap/HPV co-test in the past 5.5 years.

Exclusion Criteria4

  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Unable to communicate in English or Spanish
  • Lack valid telephone contact information
  • Report being currently pregnant.

Interventions

BEHAVIORALPRECEDE-PROCEED

delivered self-sampling (CHWSS) to increase screening participation.

Locations(2)

University of Texas at Austin

Austin, Texas, United States

M D Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06109870

Related Trials

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

NCT054915127 locations

A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV.

NCT069791801 location

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

NCT070656301 location

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

NCT051088701 location

Concordance and Acceptability of Self-screening Compared to Screening Carried Out by a Health Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV. A Randomized Controlled Crossover Study

NCT074380802 locations